细胞毒性
多西紫杉醇
体内
表皮生长因子受体
PLGA公司
体外
单克隆抗体
西妥昔单抗
化学
药理学
药物输送
癌症研究
抗体
医学
受体
癌症
生物
生物化学
免疫学
内科学
有机化学
生物技术
作者
Jitendrakumar Patel,Jitendra Amrutiya,Priyanka Bhatt,Ankit Javia,Mukul R. Jain,Ambikanandan Misra
标识
DOI:10.1080/02652048.2018.1453560
摘要
The aim of this study was to develop anti-EGFR antibody conjugated poly(lactide-co-glycolide) nanoparticles (NPs) to target epidermal growth factor receptor, highly expressed on non-small cell lung cancer cells to improve cytotoxicity and site specificity. Cetuximab was conjugated to docetaxel (DTX) loaded PLGA NPs by known EDC/NHS chemistry and characterised for size, zeta potential, conjugation efficiency and the results were 128.4 ± 3.6 nm, –31.0 ± 0.8 mV, and 39.77 ± 3.4%, respectively. In vitro release study demonstrated sustained release of drug from NPs with 25% release at pH 5.5 after 48 h. In vitro cytotoxicity studies demonstrated higher anti-proliferative activity of NPs than unconjugated NPs. Cell cycle analysis and apoptosis study were performed to evaluate extent of cell arrest at different phases and apoptotic potential for the formulations, respectively. In vivo efficacy study showed significant reduction in tumour growth and so antibody conjugated NPs present a promising active targeting carrier for tumour selective therapeutic treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI